JP7769179B2 - 前立腺がんの罹患の可能性を検査する方法 - Google Patents

前立腺がんの罹患の可能性を検査する方法

Info

Publication number
JP7769179B2
JP7769179B2 JP2022574004A JP2022574004A JP7769179B2 JP 7769179 B2 JP7769179 B2 JP 7769179B2 JP 2022574004 A JP2022574004 A JP 2022574004A JP 2022574004 A JP2022574004 A JP 2022574004A JP 7769179 B2 JP7769179 B2 JP 7769179B2
Authority
JP
Japan
Prior art keywords
ion
prostate cancer
group
measuring
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022574004A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022149487A5 (enExample
JPWO2022149487A1 (enExample
Inventor
淳文 尾添
健太郎 小林
康彦 高橋
光平 松永
孝明 佐藤
陽一 水谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Advanced Industrial Science and Technology AIST
Sumitomo Chemical Co Ltd
Original Assignee
National Institute of Advanced Industrial Science and Technology AIST
Sumitomo Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute of Advanced Industrial Science and Technology AIST, Sumitomo Chemical Co Ltd filed Critical National Institute of Advanced Industrial Science and Technology AIST
Publication of JPWO2022149487A1 publication Critical patent/JPWO2022149487A1/ja
Publication of JPWO2022149487A5 publication Critical patent/JPWO2022149487A5/ja
Application granted granted Critical
Publication of JP7769179B2 publication Critical patent/JP7769179B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7206—Mass spectrometers interfaced to gas chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G01N30/8624—Detection of slopes or peaks; baseline correction
    • G01N30/8631—Peaks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2022574004A 2021-01-07 2021-12-24 前立腺がんの罹患の可能性を検査する方法 Active JP7769179B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021001676 2021-01-07
JP2021001676 2021-01-07
PCT/JP2021/048082 WO2022149487A1 (ja) 2021-01-07 2021-12-24 前立腺がんの罹患の可能性を検査する方法

Publications (3)

Publication Number Publication Date
JPWO2022149487A1 JPWO2022149487A1 (enExample) 2022-07-14
JPWO2022149487A5 JPWO2022149487A5 (enExample) 2024-12-09
JP7769179B2 true JP7769179B2 (ja) 2025-11-13

Family

ID=82357872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574004A Active JP7769179B2 (ja) 2021-01-07 2021-12-24 前立腺がんの罹患の可能性を検査する方法

Country Status (7)

Country Link
US (1) US20240085400A1 (enExample)
EP (1) EP4276456A4 (enExample)
JP (1) JP7769179B2 (enExample)
CN (1) CN116783484A (enExample)
AU (1) AU2021417970A1 (enExample)
TW (1) TW202242412A (enExample)
WO (1) WO2022149487A1 (enExample)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515270A (ja) 2009-12-22 2013-05-02 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌の代謝学的プロファイリング
JP2013532830A (ja) 2010-07-28 2013-08-19 メタボロン，インコーポレイテッド 前立腺癌に関するバイオマーカー及びそれを使用する方法
US20160025734A1 (en) 2014-07-23 2016-01-28 Children's Medical Center Corporation Use of urinary protein biomarkers to distinguish between neoplastic and non-neoplastic disease of the prostate
JP2017203649A (ja) 2016-05-09 2017-11-16 国立大学法人大阪大学 前立腺がん判定方法
CN108344830A (zh) 2017-01-22 2018-07-31 中国科学院大连化学物理研究所 用于诊断前列腺癌的尿样组合标志物及检测试剂盒和方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10908162B2 (en) * 2017-10-27 2021-02-02 The Board Of Regents Of The University Of Texas System Methods related to volatile compounds in genitourinary cancers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515270A (ja) 2009-12-22 2013-05-02 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌の代謝学的プロファイリング
JP2013532830A (ja) 2010-07-28 2013-08-19 メタボロン，インコーポレイテッド 前立腺癌に関するバイオマーカー及びそれを使用する方法
US20160025734A1 (en) 2014-07-23 2016-01-28 Children's Medical Center Corporation Use of urinary protein biomarkers to distinguish between neoplastic and non-neoplastic disease of the prostate
JP2017203649A (ja) 2016-05-09 2017-11-16 国立大学法人大阪大学 前立腺がん判定方法
CN108344830A (zh) 2017-01-22 2018-07-31 中国科学院大连化学物理研究所 用于诊断前列腺癌的尿样组合标志物及检测试剂盒和方法

Also Published As

Publication number Publication date
EP4276456A4 (en) 2025-02-26
US20240085400A1 (en) 2024-03-14
EP4276456A1 (en) 2023-11-15
CN116783484A (zh) 2023-09-19
JPWO2022149487A1 (enExample) 2022-07-14
TW202242412A (zh) 2022-11-01
WO2022149487A1 (ja) 2022-07-14
AU2021417970A1 (en) 2023-07-27
AU2021417970A9 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
Shigeyama et al. Identification of volatile metabolites in human saliva from patients with oral squamous cell carcinoma via zeolite-based thin-film microextraction coupled with GC–MS
Silva et al. Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers—a powerful strategy for breast cancer diagnosis
EP2863227B1 (en) Means and methods for metabolic differentiation of non-alcoholic steatohepatitis from liver disease
US11136626B2 (en) Biomarkers for the diagnosis of lacunar stroke
Boonla et al. Inflammatory and fibrotic proteins proteomically identified as key protein constituents in urine and stone matrix of patients with kidney calculi
EP3070477A1 (en) Trimethylamine compounds as risk predictors of cardiovascular disease
WO2010002911A2 (en) Methods and materials for monitoring myeloma using quantitative mass spetrometry
JP6046053B2 (ja) Ｂｃｌ−２様タンパク質１１のＳＲＭ／ＭＲＭアッセイ
JP7769179B2 (ja) 前立腺がんの罹患の可能性を検査する方法
Fawzy et al. Association of Circulating Vitamin D, VDBP, and Vitamin D Receptor Expression with Severity of Diabetic Nephropathy in a Group of Saudi Type 2 Diabetes Mellitus Patients.
JP2014528082A (ja) がんの評価のための多重ｍｒｍアッセイ
JP2008533979A (ja) 生体細胞中の時間依存的な発現を防止するための試薬及び方法
US20140162903A1 (en) Metabolite Biomarkers For Forecasting The Outcome of Preoperative Chemotherapy For Breast Cancer Treatment
El-Najjar et al. A rapid liquid chromatography-tandem mass spectrometry for the quantification of fosfomycin in plasma, urine, and aqueous fluids
EP2772759B1 (en) Composition for diagnosis of lung cancer
WO2017087852A1 (en) Stress biomarkers and related non-invasive detection methods
JP6769596B2 (ja) 膀胱癌診断薬及び生体試料の判定方法
JP6830899B2 (ja) 冠動脈疾患の診断マーカー
Heier et al. Quantltation of serum complement components and plasma C3d in patients with malignant lymphoma: Relation to the stage of the tumor and circulating immune complexes
Komarevtseva et al. Alfa-1-Antitrypsin Predicts Severe COVID-19, Gastric and Renal Cancer in Conditions of Hyperglycemia
KR20250148101A (ko) 당뇨병신병증 예측 또는 진단용 바이오마커 조성물, 이를 이용한 키트 및 이를 이용한 정보제공방법
JP2018044877A (ja) 被験者における骨密度低下の発症又は進行を予測する方法
Sun et al. Exosomal circRNAs derived from cancer cells predict the prognosis of hepatocellular carcinoma after surgery: the development and validation of prognostic and recurrent nomograms
Zhang et al. Simultaneous detection and quantification of free phenol and three structural isomers of cresol in human blood using gas chromatography-triple quadrupole mass spectrometry (GC-MS/MS) and their medical reference value ranges
Nuechterlein et al. BIOM-26. GENOME-WIDE SOMATIC COPY NUMBER ALTERATION SIGNATURES HAVE PROGNOSTIC IMPLICATIONS FOR ADULT ASTROCYTIC GLIOMA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250819

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250916

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250916

R150 Certificate of patent or registration of utility model

Ref document number: 7769179

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150